Evoke Pharma Inc. (NASDAQ:EVOK) – Research analysts at FBR & Co issued their Q1 2017 earnings estimates for shares of Evoke Pharma in a report released on Tuesday. FBR & Co analyst V. Bernardino anticipates that the brokerage will post earnings per share of ($0.17) for the quarter. FBR & Co has a “Outperform” rating and a $9.00 price objective on the stock. FBR & Co also issued estimates for Evoke Pharma’s Q2 2017 earnings at ($0.18) EPS, Q3 2017 earnings at ($0.18) EPS, Q4 2017 earnings at ($0.17) EPS, FY2018 earnings at $1.39 EPS, FY2019 earnings at $2.18 EPS and FY2020 earnings at $1.63 EPS.

Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.03. During the same quarter in the previous year, the business posted ($0.42) earnings per share.

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

A number of other equities analysts have also recently issued reports on EVOK. Noble Financial cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. HC Wainwright set a $2.50 target price on shares of Evoke Pharma and gave the stock a “hold” rating in a report on Tuesday, August 16th. Finally, Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $2.50 price target on the stock in a report on Wednesday, October 5th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $9.88.

Shares of Evoke Pharma (NASDAQ:EVOK) traded up 7.36% during midday trading on Wednesday, reaching $1.75. The company’s stock had a trading volume of 308,165 shares. The stock’s market capitalization is $21.61 million. Evoke Pharma has a 12 month low of $1.35 and a 12 month high of $11.11. The stock’s 50 day moving average is $1.87 and its 200 day moving average is $3.62.

A number of large investors have recently made changes to their positions in EVOK. State Treasurer State of Michigan boosted its stake in shares of Evoke Pharma by 460.0% in the third quarter. State Treasurer State of Michigan now owns 140,000 shares of the specialty pharmaceutical company’s stock valued at $316,000 after buying an additional 115,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Evoke Pharma by 5.0% in the second quarter. Vanguard Group Inc. now owns 62,381 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 2,947 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Evoke Pharma by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 23,679 shares of the specialty pharmaceutical company’s stock valued at $162,000 after buying an additional 464 shares during the last quarter. 9.15% of the stock is currently owned by hedge funds and other institutional investors.

Evoke Pharma Company Profile

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

5 Day Chart for NASDAQ:EVOK

Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.